Home › NDC Lookup › RxCUI directory › RxCUI 2700805

5 ML hyaluronidase-nvhy 2000 UNT/ML / nivolumab-nvhy 120 MG/ML Injection [Opdivo Qvantig] — RxCUI 2700805

RxNorm drug concept · Semantic branded drug
RxCUI 2700805 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2700805
Official name5 ML hyaluronidase-nvhy 2000 UNT/ML / nivolumab-nvhy 120 MG/ML Injection [Opdivo Qvantig]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asOpdivo Qvantig (nivolumab-hyaluronidase-nvhy 600 MG / 10,000 UNT) per 5 ML Injection; OPDIVO Qvantig 600 MG / 10,000 UNT in 5 ML Injection
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)145 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Nivolumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Great question. Unlike chemotherapy, which directly attacks cancer cells (and can harm healthy cells too), Opdivo works by releasing the brakes on your own immune system. It blocks...
  • What exactly does Opdivo do, and how is it different from regular chemotherapy?
  • No, Opdivo isn't a pill. It's given as an IV infusion directly into your vein at an infusion center or clinic. Each session typically takes about 30 minutes. Depending on your spec...
  • How will I actually receive this medication — do I take it as a pill?
📖 Read our full Nivolumab Injection guide →

🕸️ Concept Web — How 5 ML hyaluronidase-nvhy 2000 UNT/ML / nivolumab-... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 5 ML hyaluronidase-nvhy 2000 UNT/ML / nivolumab-nvhy 120 MG/ML Injection [Opdivo Qvantig] RxCUI 2700805

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Hyaluronidase 5464
    • Nivolumab 1597876
    • Hyaluronidase / nivolumab 2700793
    • Hyaluronidase-nvhy 2700789
    • Nivolumab-nvhy 2700791
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Opdivo Qvantig 2700800
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Hyaluronidase / nivolumab Injection 2700795
    • Hyaluronidase-nvhy / nivolumab-nvhy Injection 2700797
    • Hyaluronidase / nivolumab Injectable Product 2700794
    • Hyaluronidase-nvhy / nivolumab-nvhy Injectable Product 2700796
    • Hyaluronidase / nivolumab Injection [Opdivo Qvantig] 2700803
    • Hyaluronidase-nvhy / nivolumab-nvhy Injection [Opdivo Qvantig] 2700804
    • Opdivo Qvantig Injectable Product 2700802
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 18 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 5 ML hyaluronidase-nvhy 2000 UNT/ML / nivolumab-nvhy 120 MG/ML Injection SCD · 2700798
  • Hyaluronidase-nvhy 2000 UNT/ML SCDC · 2700790
  • Nivolumab-nvhy 120 MG/ML SCDC · 2700792
  • Hyaluronidase / nivolumab Injection SCDF · 2700795
  • Hyaluronidase-nvhy / nivolumab-nvhy Injection SCDFP · 2700797
  • Hyaluronidase / nivolumab Injectable Product SCDG · 2700794
  • Hyaluronidase-nvhy / nivolumab-nvhy Injectable Product SCDGP · 2700796

Brand-Name Concepts

  • Hyaluronidase-nvhy 2000 UNT/ML / nivolumab-nvhy 120 MG/ML [Opdivo Qvantig] SBDC · 2700801
  • Hyaluronidase / nivolumab Injection [Opdivo Qvantig] SBDF · 2700803
  • Hyaluronidase-nvhy / nivolumab-nvhy Injection [Opdivo Qvantig] SBDFP · 2700804
  • Opdivo Qvantig Injectable Product SBDG · 2700802
  • Opdivo Qvantig BN · 2700800

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2700805 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00003-3120-01 1 VIAL, SINGLE-DOSE in 1 CARTON (0003-3120-01) / 2.5 mL in... OPDIVO QVANTIG E.R. Squibb & Sons, L.L.C. 2025-11-24
00003-6120-01 1 VIAL, SINGLE-DOSE in 1 CARTON (0003-6120-01) / 5 mL in 1... OPDIVO QVANTIG E.R. Squibb & Sons, L.L.C. 2025-01-02
Observed labelers: E.R. Squibb & Sons, L.L.C. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9289 Inj nivolumab 2 mg hyaluron 2 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.